BALTIMORE, Md--The results of a phase III double-blind trial of
Guilford Pharmaceutical Inc.'s Gliadel have been published in
Lancet (April 22, 1995). In patients with malignant brain tumors,
6-month median survival rates increased from 23 weeks with placebo
to 31 weeks with Gliadel treatment, the company said. For patients
with glioblastoma multiforme, the increase was from 20 weeks to
28 weeks, a 55% improvement.
Gliadel is a biodegradable polymer wafer containing carmustine
in the polymer matrix. Up to eight wafers are implanted into the
cavity created by tumor removal, thus overcoming the limitations
of IV carmustine.
The trial, led by Henry Brem, MD, of Johns Hopkins, involved 222
patients at 27 centers.